Phase I and Pharmacokinetic Study ofVorinostat , AHistone Deacetylase Inhibitor , in Combinationwith Carboplatin and Paclitaxel forAdvanced Solid Malignancies

@inproceedings{Ramalingam2007PhaseIA,
  title={Phase I and Pharmacokinetic Study ofVorinostat , AHistone Deacetylase Inhibitor , in Combinationwith Carboplatin and Paclitaxel forAdvanced Solid Malignancies},
  author={Suresh S Ramalingam and Robert A Parise and Ramesh K. Ramananthan and Theodore F. Lagattuta and Lori A. Musguire and Ronald G. Stoller and DouglasM. Potter and Athanassios E. Argiris and James A. Zwiebel and MerrillJ. Egorin and Chandra Prakash Belani},
  year={2007}
}
Purpose:The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel. Experimental Design: Patients (N = 28) with advanced solid malignancies were treated with vorinostat, administered orally once daily for 2 weeks or twice daily for 1week, every 3 weeks. Carboplatin and paclitaxel were administered i.v. once every 3 weeks. Doses of vorinostat and… CONTINUE READING